Need a specific person's email?
Browse American Preclinical Services, Now Part of NAMSA's employee directory (about 75 employees) and reveal verified emails free.
American Preclinical Services, Now Part of NAMSA's most common email format is First.Last@americanpreclinical.com (ex. John.Doe@americanpreclinical.com), used for 49% of americanpreclinical.com addresses. American Preclinical Services, Now Part of NAMSA uses 5 email patterns across 2 domains: americanpreclinical.com and apsemail.com. Percentages are the share of addresses within each domain.
| Format | Example | Share of americanpreclinical.com |
|---|---|---|
| First.Last@americanpreclinical.comMost common | John.Doe@americanpreclinical.com | |
| FLast@americanpreclinical.com | JDoe@americanpreclinical.com | |
| First@americanpreclinical.com | John@americanpreclinical.com | |
| F.Last@americanpreclinical.com | J.Doe@americanpreclinical.com |
| Format | Example | Share of apsemail.com |
|---|---|---|
| FLast@apsemail.comMost common | JDoe@apsemail.com |
Browse American Preclinical Services, Now Part of NAMSA's employee directory (about 75 employees) and reveal verified emails free.
Research ServicesMinnesota, United States51-200 Employees
American Preclinical Services (APS), now part of NAMSA, operates as a contract research organization focused on preclinical testing for medical devices and pharmaceuticals. Based in Minneapolis, Minnesota, APS maintains accreditations and registrations including AAALAC, ISO17025, USDA, and GLP compliance, supporting a broad range of biocompatibility, toxicology, pharmacology, and pathology services. The company positions itself as a center of excellence with capabilities spanning interventional, surgical, and bioskills activities, along with animal model development and comprehensive pathology, aimed at advancing product development timelines for both startups and established industry players. Its value lies in delivering rapid, flexible study design and execution from initial feasibility and screening through GLP safety studies, aligning with the fast-paced demands of product development. A notable recent development includes a collaboration with Recombinetics in 2020 to pursue a glioblastoma-related study, illustrating engagement with partners on specialized preclinical research.
Most common format
First.Last@americanpreclinical.com
Example: John.Doe@americanpreclinical.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.